Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Apr;106(4):407-12.
doi: 10.1111/cas.12622. Epub 2015 Mar 9.

Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303)

Masayuki Shinoda  1 , Nobutoshi Ando, Ken Kato, Satoshi Ishikura, Hoichi Kato, Yasuhiro Tsubosa, Keiko Minashi, Hiroshi Okabe, Yusuke Kimura, Tatsuyuki Kawano, Shin-Ichi Kosugi, Yasushi Toh, Kenichi Nakamura, Haruhiko Fukuda; Japan Clinical Oncology Group
Affiliations
Clinical Trial

Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303)

Masayuki Shinoda et al. Cancer Sci. 2015 Apr.

Abstract

Low-dose cisplatin and 5-fluorouracil (LDPF) chemotherapy with daily radiotherapy (RT) is used as an alternative chemoradiotherapy regimen for locally advanced esophageal carcinoma. We evaluated whether RT plus LDPF chemotherapy had an advantage in terms of survival and/or toxicity over RT plus standard-dose cisplatin and 5-fluorouracil (SDPF) chemotherapy in this study. This multicenter trial included esophageal cancer patients with clinical T4 disease and/or unresectable regional lymph node metastasis. Patients were randomly assigned to receive RT (2 Gy/fraction, total dose of 60 Gy) with SDPF (arm A) or LDPF (arm B) chemotherapy. The primary endpoint was overall survival (OS). A total of 142 patients (arm A/B, 71/71) from 41 institutions were enrolled between April 2004 and September 2009. The OS hazard ratio in arm B versus arm A was 1.05 (80% confidence interval, 0.78-1.41). There were no differences in toxicities in either arm. Arm B was judged as not promising for further evaluation in the phase III setting. Thus, the Data and Safety Monitoring Committee recommended that the study be terminated. In the updated analyses, median OS and 3-year OS were 13.1 months and 25.9%, respectively, for arm A and 14.4 months and 25.7%, respectively, for arm B. Daily RT plus LDPF chemotherapy did not qualify for further evaluation as a new treatment option for patients with locally advanced unresectable esophageal cancer. This study was registered at the UMIN Clinical Trials Registry as UMIN000000861.

Keywords: Chemoradiotherapy; esophageal squamous cell carcinoma; randomized trial; survival; toxicity.

PubMed Disclaimer

Figures

Fig 1
Fig 1
CONSORT flow diagram of a multicenter phase II trial of radiotherapy (2 Gy/fraction, total dose of 60 Gy) and standard-dose cisplatin and 5-fluorouracil (SDPF-RT; arm A) or low-dose cisplatin and 5-fluorouracil (LDPF-RT; arm B) chemotherapy in esophageal cancer patients with clinical T4 disease and/or unresectable regional lymph node metastasis.
Fig 2
Fig 2
Overall survival (OS) of 139 eligible patients with esophageal cancer with clinical T4 disease and/or unresectable regional lymph node metastasis treated with radiotherapy (2 Gy/fraction, total dose of 60 Gy) and standard-dose cisplatin and 5-fluorouracil (SDPF-RT; arm A) or low-dose cisplatin and 5-fluorouracil (LDPF-RT; arm B). M, months; MST, median survival time.
See this image and copyright information in PMC

References

    1. Comprehensive Registry of Esophageal Cancer in Japan (1998, 1999) & Long-Term Results of Esophagectomy in Japan (1988–1997. 3rd edn. Tokyo: The Japanese Society for Esophageal Diseases; 2002.
    1. Matsubara T, Ueda M, Kokubo N, et al. Role of esophagectomy in treatment of esophageal carcinoma with clinical evidence of adjacent organ invasion. World J Surg. 2001;25:279–84. - PubMed
    1. Ikeda K, Ishida K, Sato N, et al. Chemoradiotherapy followed by surgery for thoracic esophageal cancer potentially or actually involving adjacent organs. Dis Esophagus. 2001;14:197–201. - PubMed
    1. Ishida K, Ando N, Yamamoto S, et al. Phase II study of cisplatin and 5- fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group(JEOG)/Japan Clinical Oncology Group Trial(JCOG 9516) Jpn J Clin Oncol. 2004;34:615–9. - PubMed
    1. Fujita H, Sueyoshi S, Tanaka T, et al. Esophagectomy: is it necessary after chemoradiotherapy for a locally advanced T4 esophageal cancer? Prospective nonrandomized trial comparing chemoradiotherapy with surgery versus without surgery. World J Surg. 2005;29:25–30. - PubMed

Publication types

MeSH terms